EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Clinical Trials Landscape for Alzheimer's Disease

Guoping Shen iD, Xue Xu iD, Minping Li iD, Zaiyuan Sun iD, Linyu Wei iD, Zhezhi Deng iD, Zehuang Lin iD, Jianwen Huang iD, Weiwei Qi iD, Jia Xu iD

CNS Neuroscience & Therapeutics · 2025-06 · 31 (6)

DOI: 10.1111/cns.70492 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 26.06.2025. Verfasst von Guoping Shen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, PR China. Hauptthemen laut MEDLINE: Alzheimer Disease, Clinical Trials as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangzhou Science and Technology Program Project, Natural Science Foundation of Guangdong Province, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Not only drug and non‐drug development but also non‐therapeutic research in Alzheimer's disease (AD) clinical trials is unclear.

Methods

The participants were AD clinical trials obtained from the clinicaltrials.gov registry. The research objectives and interventions of those trials were analyzed. Bibliometric network analysis of those published articles in PubMed was also conducted.

Results

A total of 1681 clinical trials and 565 corresponding published articles in the past 20 years were included in the analysis. “Safety”, “dose”, “adverse events”, and “biomarker” were the most frequently used words that appeared in the title or abstract of published articles. The top three classes of 362 drugs were anti‐Amyloid, enhancing acetylcholine, neurotransmitter, or targeting its receptor. The physical therapy, diet, and cognitive training ranked as the first three classes of non‐drug therapy. Imaging, risk factors, and molecular biomarkers were the three most abundant categories in non‐therapeutic research, and three fields of prevention, risk factors, and the dental or intestinal microbiome showed an escalated trend (All P trend < 0.05). Dissusion The results described a comprehensive landscape for the clinical studies of AD. Although most drugs treated AD abortively, the success of lecanemab and decanemab provides confidence for us to further study the pathogenesis of AD and explore new therapeutic targets to develop anti‐AD drugs. Rising non‐drug and non‐therapeutic research will provide more possible methods for the treatment and prevention of AD in thefuture.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseClinical Trials as TopicHumans

Stichwörter der Autor:innen

Alzheimer's diseaseclinical trialscognitiondementialandscape

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, PR China.
  • Department of Neurology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, PR China.
  • Department of Emergency, The Seventh Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, PR China.
  • Department of Emergency, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, PR China.

ORCID-Profile: Guoping Shen, Xue Xu, Minping Li, Zaiyuan Sun, Linyu Wei, Zhezhi Deng, Zehuang Lin, Jianwen Huang, Weiwei Qi, Jia Xu

Förderung

  • Guangzhou Science and Technology Program Project
  • Natural Science Foundation of Guangdong Province
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Shen, G., Xu, X., Li, M., Sun, Z., Wei, L., Deng, Z., Lin, Z., Huang, J., Qi, W., & Xu, J. (2025). The Clinical Trials Landscape for Alzheimer's Disease. CNS Neuroscience & Therapeutics, 31(6). https://doi.org/10.1111/cns.70492

Vancouver

Shen G, Xu X, Li M, Sun Z, Wei L, Deng Z, et al. The Clinical Trials Landscape for Alzheimer's Disease. CNS Neuroscience & Therapeutics. 2025;31(6). doi:10.1111/cns.70492

BibTeX
@article{Shen2025,
  author = {Shen, Guoping and Xu, Xue and Li, Minping and Sun, Zaiyuan and Wei, Linyu and Deng, Zhezhi and Lin, Zehuang and Huang, Jianwen and Qi, Weiwei and Xu, Jia},
  title = {The Clinical Trials Landscape for Alzheimer's Disease},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  volume = {31},
  number = {6},
  doi = {10.1111/cns.70492}
}
Kostenlos starten →